About

Born New York 1957 to Irish emigrants (Leitrim and Kildare). Moved to Ireland 1967.

Education: Patrician Brothers NS Newbridge, Synge St., Terenure College and University College Dublin. Trained in cancer medicine in New York in Mount Sinai Hospital and Memorial Sloan- Kettering Cancer Centre. Appointed consultant St. Vincent’s in 1993.

Founded Irelands first national cancer treatment research group-ICORG in 1997. ICORG now has 100 employees nationally and brings in millions of Euro worth of free cancer drugs to our health service.

Chairman of Molecular Therapeutics for Cancer Ireland. Lectured in more than 40 countries. Degrees in medicine, science and business administration. Awarded professorships in cancer research from Dublin City University and University College Dublin.

Author of 150 research papers. Regular columnist for Sunday Independent. Has also written in Times, Irish Independent, Mail, Sunday Business Post, Business and Finance.

Recipient of awards from the American Cancer Society, European Society of Medical Oncology.

Three children, Katie, Jack and Mia Jane

Curriculum Vitae

CAREER SUMMARY
Professor Crown received his medical training at the University College Dublin. He received his postdoctoral training on both sides of the Atlantic and went on to complete his fellowship training in oncology at Mount Sinai Medical Centre and in haematology/oncology at Memorial Sloan Kettering Cancer Centre. He served as assistant professor at Cornell University Medical College and assistant member at Memorial Sloan Kettering Cancer Centre before joining St. Vincent’s University Hospital in 1993.

The Clinical Trials Unit which he founded at St. Vincent’s University Hospital (SVUH) has developed an international leadership role in oncology trials, and 11,000 women around the world have now been enrolled on six randomised trials which were chaired or co-chaired by Professor Crown. In recent years, Professor Crown has developed an inter-institutional programme of bi-directional translational breast cancer research in collaboration with Professor Martin Clynes (NICB), Professor Joe Duffy and Dr Susan Kennedy (SVUH/UCD), and Professor Dennis Slamon, (UCLA). The research team includes senior scientists, postdoctoral scientists and postgraduate students at these sites, in addition to his clinical research staff. Professor Crown was awarded a Health Research Board (HRB) Clinician Scientist Award in 2007, which provides protected time for research. As a result Professor Crown now has an increasing involvement at the clinical-laboratory research interface, where he provides direction for laboratory research which addresses questions arising from clinical observations and also designs and implements clinical research based on laboratory-derived hypotheses.

Prior to 1997, Ireland, uniquely in Western Europe, had no clinical trials group. Professor Crown together with Professor John Armstrong, founded the Irish Clinical Oncology Research Group (ICORG). In 2000, with the aid of funding from the HRB, the group expanded its membership to include additional members in Northern Ireland. Today it has 283 members including 95% of cancer-treating consultants in Ireland. ICORG has now recruited over 3,000 patients on 52 clinical trials, including 1200 patients recruited to 26 breast cancer trials. The portfolio of studies consists of internally generated trials, collaborative studies with international academic clinical trial groups (BIG, BCIRG, ACCOG, ECOG, NSABP), and industrial collaborations. ICORG was the first non-North American group invited to join NSABP. Professor Crown served as chairman of the ICORG Breast Cancer Disease Specific Sub-group (DSSG) since its foundation in 1998, and has recently been re-elected to this position for a further four years and is chair of the newly established ICORG Melanoma DSSG. Professor Crown is also a frequent contributor to the lay press, and professional meetings, on the subject of health policy.

TRAINING
Internship: Mater Hospital Dublin, 1980-1981
BSc tutor/Pathology Demonstrator: University College Dublin, 1981-1982
Senior House Officer: Federated Dublin Voluntary Hospitals/Trinity College Dublin Training Scheme in Internal Medicine, 1982-1984
Registrar: Gastroenterology and General Medicine, Guy’s Hospital London, 1984
Haematology, St. James’s Hospital, Dublin, 1984-1985
Fellow: Oncology, Mount Sinai Medical Centre (NY), 1985-1987
Haematology/Oncology, Memorial Sloan Kettering Cancer Centre, 1987-1989

EMPLOYMENT
HRB Clinician Scientist: 2008-2013
Newman Clinical Research Professor: University College Dublin, 2005-Present
Professorial Chair: Thomas Baldwin Chair in Cancer Research, Dublin City University, 2003-Present
Consultant Physician (Medical Oncologist): St Vincent’s University Hospital group, Dublin and St Luke’s/St Anne’s Hospital Dublin July 1993-Present
Assistant Member: Memorial Sloan-Kettering Cancer Centre 1992-1993
Assistant Attending: Memorial Hospital for Cancer and Allied Diseases 1992-1993
Assistant Professor: Cornell University Medical College 1992-1993.
Clinical Assistant Physician (Consultant): Memorial Sloan-Kettering Cancer Centre, 1989-1992
Instructor: Cornell University Medical College 1989-1992

SPECIALTY CERTIFICATIONS
1983 Member of the Royal College of Physicians of Ireland
1990 Diplomate American Board of Internal Medicine
1991 Diplomate A.B.I.M. Oncology Subspecialty (96th Centile in U.S.)
Diplomate European Society of Medical Oncology

THESES
MBA (1st Class Honours): “Learning from out past, Understanding our present, Shaping our Future: A Strategy for European Medical Oncology in the New Millennium”.
MD: “New strategies for hematopoietic support of dose intensive cancer chemotherapy,” 2001.

LEADERSHIP POSITIONS
Irish Clinical Oncology Research Group (Founder and Chairman 1997 – 2000).
Anglo-Celtic Oncology Group (Founder and Co-Chairman).
European Breast Cancer Dose Intensity Study (Founder and Chairman).
Chairman Cancer Research Advancement Board of the Irish Cancer Society (1997-1999)
Chairman Department of Medical Oncology, St. Luke’s Hospital
Irish National Representative ESMO (1998 – )
Drugs and Therapeutic Committee, St. Luke’s Hospital (Chairman 1996-7).
National Representative ESMO – 1998-2000
Chairman Breast Committee, ICORG 1998-present
Chemotherapy Sub-Committee, BCIRG – 2003-2005
Education Committee, ASCO – 2004-2006
Chairman Melanoma Committee, ICORG – 2008-present

SCIENTIFIC AND MEDICAL SOCIETIES:
American Society of Clinical Oncology.
American Association for Cancer Research.
New York Metropolitan Breast Cancer Group.
European Society of Medical Oncology
Irish Society of Medical Oncology (Founder Member).
Irish Clinical Oncology Research Group (Founding Chairman)
Cellular Therapy Group (Founder Member).
EORTC Breast Cancer Cooperative Group
Breast Cancer International Research Group (BCIRG)

COMMITTEE MEMBERSHIPS
St. Luke’s Institute for Cancer research, Research Management Committee.
Member Solid Tumour Working Party European Blood, Marrow Transplant Group
BCIRG Scientific Committee

HONOURS AND AWARDS
Honours in Internal Medicine 1980
Honours BSc in Pathology 1982
American Cancer Society Clinical Oncology Career Development Award (1991-93)
St. Luke’s Lecture and Gold Medal 1999
1st Class Honours Master of Business Administration UCD/ RCSI 1999
UCD Business School – Dean’s List 2000
Journal of Medical Science (JMS) Doctor Award for Oncology, 2001
Merit Award European Society of Medical Oncology (ESMO), 2002
JMS Oncology and best overall paper awards, 2005

TEACHING

University College Dublin undergraduate medical students & UCD Oncology Nursing
Dublin City University undergraduate biotechnology students
RCSI / UCD MBA “Cancer Services in Ireland”
St. Luke’s Hospital Oncology Nursing Certificate
Member of European School of Oncology Teaching Faculty

CLINICAL DEVELOPMENT OF DRUGS
Taxotere: chaired clinical trials and made successful presentation to the Oncology Drug Approval Committee of the Food and Drug Administration.
Herceptin: chaired licensing clinical trials for Herceptin.
Lapatinib: participant and author on licensing trials for lapatinib.

CLINICAL STUDIES (chaired or co-chaired by Prof Crown)
Anglo-Celtic I: Prospective Randomised Evaluation of High Study Intensity Chemotherapy with Peripheral Blood Progenitor Support in patients with High Risk Breast Cancer.

IRE 201: Phase I-II Study of Docetaxol in 201 combination with Ifosfamide and Cisplatin in patients with Advanced Non-Small Cell Lung Cancer.

ICORG: An Open Non-Randomised Pilot Study to Assess the Efficacy and Safety of Multi- Course, High-Dose Chemotherapy using Taxol (Paclitaxel), Cyclophosphamide, Carboplatin, Melphalan and Thiotepa in patients with Advanced Ovarian Cancer.

ICORG: Non-Autograft Requiring Multi-Cycle High- Dose Chemotherapy in patients with Poor Risk Non-Hodgkin’s Lymphoma.

ICORG: Phase I Evaluation of Escalating Dose Daunoxome as a Component of Combination
chemotherapy in patients with Untreated or Minimally Pretreated Non-Hodgkin’s
lymphoma.

EBDIS 1: Multi-Cycle High Dose Chemotherapy Versus Optimised Conventionally Dosed
Chemotherapy in patients with Metastatic Breast Cancer: A Prospective Randomised Trial.
BIG-2-98: Feasibility of Two Sequential Chemotherapy Regimens of Different Dose Intensity given as First Line Chemotherapy Treatment for Locally Advanced or High Risk Early Breast Carcinoma.

RPR 038: A Dose Finding Study of Docetaxel in Combination with Cisplatin as First Line
Chemotherapy in patients with Metastatic Breast Carcinoma.

BCIRG 007: Phase III Trial of Trastuzmab (Herceptin) in Combination with Docetaxel (Taxotere), or Docetaxel Plus Platinum coordination Complexes as Initial Chemotherapy for HER-2-Neu Overexpressing Metastatic Breast Cancer.

BCIRG 006: Multicenter Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide followed by Docetaxel (AC->T) with Doxorubicin and Cyclophosphamide followed by Docetaxel and Trastuzumab (AC->TH) and with Docetaxel, Platinum s in the Treatment of Node Positive and High Risk Node Negative Adjuvant Patients with Operable Breast Cancer Containing the Her2Neu Alteration.

BCIRG 005: A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination with Doxorubicin and Cyclophosphamide (TAC) versus Doxorubicin and Cyclophosphamide followed by Docetaxel (AC–>T) as Adjuvant Treatment of Operable Breast Cancer Her2Neu Negative Patients with Positive Axillary Lymph Nodes.

BCIRG 001: Phase II Trial of Trastuzumab in combination with Docetaxel and Platinum Salt in Metastatic Breast Cancer.

Comments
One Response to “About”
  1. whelanm@irishpride.ie says:

    you are the best thank you

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: